Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: A randomized, prospective trial

Obesity Surgery

Volumn 22, Issue 5, 2012, Pages 740-748

  Peterli, Ralph ^a   Steinert, Robert E ^b   Woelnerhanssen, Bettina ^b   Peters, Thomas ^a   Christoffel Courtin, Caroline ^a   Gass, Markus ^a   Kern, Beatrice ^a   Von Fluee, Markus ^a   Beglinger, Christoph ^b  

^a St Claraspital AG   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Cholecystokinin (CCK); Ghrelin; Glucagon like peptide 1 (GLP 1); Glycemic control; Gut hormones; Laparoscopic; Laparoscopic sleeve gastrectomy; Metabolic surgery; Peptide YY (PYY); Roux en Y gastric bypass

Indexed keywords

CHOLECYSTOKININ; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PEPTIDE YY;

ADULT; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HOMA INDEX; HORMONAL REGULATION; HORMONE BALANCE; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INTERMETHOD COMPARISON; LAPAROSCOPIC SURGERY; MALE; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; STOMACH BYPASS; WEIGHT REDUCTION;

ADULT; BLOOD GLUCOSE; CHOLECYSTOKININ; FEMALE; GASTRIC BYPASS; GASTROINTESTINAL HORMONES; GASTROPLASTY; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LAPAROSCOPY; MALE; OBESITY, MORBID; PEPTIDE YY; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; WEIGHT LOSS;

EID: 84862661746     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-012-0622-3     Document Type: Article

References (40)

1. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-93. (Pubitemid 39665322)
2. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724-37. (Pubitemid 39346675)
3. Cummings DE, Overduin J, Foster-Schubert KE, et al. Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg Obes Relat Dis. 2007;3:109-15. (Pubitemid 46444709)
4. MacDonald Jr KG, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg. 1997;1:213-20. discussion 220.
5. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339-50. discussion 350-332.
6. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467-84. discussion 484-465.
7. Thaler JP, Cummings DE. Minireview: hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology. 2009;150:2518-25.
8. Kim S, Richards WO. Long-term follow-up of the metabolic profiles in obese patients with type 2 diabetes mellitus after Roux-en-Y gastric bypass. Ann Surg. 2010;251:1049-55.
9. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753-61. (Pubitemid 47295642)
10. Nguyen NT, Root J, Zainabadi K, et al. Accelerated growth of bariatric surgery with the introduction of minimally invasive surgery. Arch Surg. 2005;140:1198-202. discussion 1203.
11. Shi X, Karmali S, Sharma AM, et al. A review of laparoscopic sleeve gastrectomy for morbid obesity. Obes Surg. 2010;20:1171-7.
12. Gagner M, Gumbs AA, Milone L, et al. Laparoscopic sleeve gastrectomy for the super-super-obese (body mass index >60 kg/m(2)). Surg Today. 2008;38:399-403. (Pubitemid 351624445)
13. Nocca D, Krawczykowsky D, Bomans B, et al. A prospective multicenter study of 163 sleeve gastrectomies: results at 1 and 2 years. Obes Surg. 2008;18:560-5.
14. Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg. 2008;247:401-7.
15. Peterli R, Wolnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250:234-41.
16. Menenakos E, Stamou KM, Albanopoulos K, et al. Laparoscopic sleeve gastrectomy performed with intent to treat morbid obesity: a prospective single-center study of 261 patients with a median follow-up of 1 year. Obes Surg. 2010;20:276-82.
17. Shah S, Shah P, Todkar J, et al. Prospective controlled study of effect of laparoscopic sleeve gastrectomy on small bowel transit time and gastric emptying half-time in morbidly obese patients with type 2 diabetes mellitus. Surg Obes Relat Dis. 2010;6:152-7.
18. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004;89:2608-15. (Pubitemid 38766339)
19. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741-9. (Pubitemid 44629948)
20. Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236-42. (Pubitemid 38963013)
21. le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108-14. (Pubitemid 43054062)
22. Gass M, Beglinger C, Peterli R. Metabolic surgery-principles and current concepts. Langenbecks Arch Surg. 2011;396:949-72.
23. Rubino F, Schauer PR, Kaplan LM, et al. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010;61:393-411.
24. Garcia de la Torre N, Rubio MA, Bordiu E, et al. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab. 2008;93:4276-81. (Pubitemid 352789522)
25. Gaylinn BD, Thorner MO. Luminal influences to orchestrate gastroenterological hormone secretion: the fat, long-chain fatty acid, cholecystokinin, glucagon-like peptide 1 axis. J Clin Endocrinol Metab. 2010;95:503-4.
26. Beglinger S, Drewe J, Schirra J, et al. Role of fat hydrolysis in regulating glucagon-like peptide-1 secretion. J Clin Endocrinol Metab. 2010;95:879-86.
27. Sugerman HJ, Wolfe LG, Sica DA, et al. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg. 2003;237:751-6.
28. Woelnerhanssen B, Peterli R, Steinert RE et al. Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy - a prospective randomized trial. Surg Obes Relat Dis 2011.
29. Lee WJ, Chong K, Lee YC, et al. Effects of obesity surgery on type 2 diabetes mellitus Asian patients. World J Surg. 2009;33:1895-903.
30. Lee WJ, Ser KH, Chong K, et al. Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change of insulin secretion. Surgery. 2010;147:664-9.
31. Melissas J, Daskalakis M, Koukouraki S, et al. Sleeve gastrectomy - a "food limiting" operation. Obes Surg. 2008;18:1251-6.
32. Melissas J, Koukouraki S, Askoxylakis J, et al. Sleeve gastrectomy: a restrictive procedure? Obes Surg. 2007;17:57-62.
33. Baumann T, Kuesters S, Grueneberger J, et al. Time-resolved MRI after ingestion of liquids reveals motility changes after laparoscopic sleeve gastrectomy - preliminary results. Obes Surg. 2011;21:95-101.
34. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002;418:650-4.
35. Boey D, Lin S, Enriquez RF, et al. PYY transgenic mice are protected against diet-induced and genetic obesity. Neuropeptides. 2008;42:19-30.
36. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623-30. (Pubitemid 34755670)
37. Garcia-Fuentes E, Garrido-Sanchez L, Garcia-Almeida JM, et al. Different effect of laparoscopic Roux-en-Y gastric bypass and open biliopancreatic diversion of Scopinaro on serum PYY and ghrelin levels. Obes Surg. 2008;18:1424-9.
38. Wortley KE, del Rincon JP, Murray JD, et al. Absence of ghrelin protects against early-onset obesity. J Clin Invest. 2005;115:3573-8. (Pubitemid 43121845)
39. Zigman JM, Nakano Y, Coppari R, et al. Mice lacking ghrelin receptors resist the development of diet-induced obesity. J Clin Invest. 2005;115:3564-72. (Pubitemid 43121844)
40. Kirchner H, Tong J, Tschop MH, et al. Ghrelin and PYY in the regulation of energy balance and metabolism: lessons from mouse mutants. Am J Physiol Endocrinol Metab. 2010;298:E909-19.